Charite Medical University of Berlin commences Mologen renal cancer drug study - Pharmaceutical Business Review PDF Print
Pharmaceutical Business Review
The Charite - Medical University of Berlin has begun the implementation of the clinical study phase I/II with Mologen's renal cancer medication MGN1601

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.